Andrew Hooker
Professor at Department of Pharmacy; Pharmacometrics
- Mobile phone:
- +46 70 167 90 48
- E-mail:
- andrew.hooker@uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Andrew Hooker at Department of Pharmacy; Pharmacometrics
- ORCID:
- 0000-0002-2676-5912
Short presentation
My research is focused on pharmacometrics (PKPD). Topics include optimal experimental design, methodological problems associated with building and evaluating PKPD models, modeling discrete data, and the development and use of PKPD models in a range of therapeutic areas and drug classes including cancer, addiction, PET, progressive disorders, and biologics. I also develop a number of software programs for pharmacometrics.
I teach courses in statistics, drug development, and pharmacometrics.
Keywords
- free and open source software
- pharmacometrics
- pkpd
- optimal experimental design
- optimal design
- population models
- nonlinear mixed-effects models

Publications
Selection of publications
The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA
Part of AAPS Journal, 2024
Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
Part of Orphanet Journal of Rare Diseases, 2023
- DOI for Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
- Download full text (pdf) of Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
Part of CPT, p. 624-630, 2023
- DOI for Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop
- Download full text (pdf) of Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop
Part of AAPS Journal, 2021
- DOI for Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
- Download full text (pdf) of Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Pharmacometrics meets statistics-A synergy for modern drug development
Part of CPT, p. 1134-1149, 2021
- DOI for Pharmacometrics meets statistics-A synergy for modern drug development
- Download full text (pdf) of Pharmacometrics meets statistics-A synergy for modern drug development
Metaheuristics for pharmacometrics
Part of CPT, p. 1297-1309, 2021
- DOI for Metaheuristics for pharmacometrics
- Download full text (pdf) of Metaheuristics for pharmacometrics
Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
Part of CPT, p. 1452-1465, 2021
- DOI for Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
- Download full text (pdf) of Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
Part of Clinical Pharmacology and Therapeutics, p. 1190-1195, 2021
- DOI for Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
- Download full text (pdf) of Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
Part of Clinical Pharmacology in Drug Development, p. 220-228, 2021
Part of AAPS Journal, 2020
- DOI for Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
- Download full text (pdf) of Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
Part of AAPS Journal, 2020
- DOI for Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models
- Download full text (pdf) of Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models
Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis
Part of Antimicrobial Agents and Chemotherapy, 2020
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models
Part of AAPS Journal, 2019
Part of AAPS Journal, 2018
- DOI for Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group
- Download full text (pdf) of Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group
Part of AAPS Journal, 2018
- DOI for Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
- Download full text (pdf) of Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations
Part of AAPS Journal, 2018
Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
Part of AAPS Journal, 2018
- DOI for Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
- Download full text (pdf) of Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Part of AAPS Journal, 2018
- DOI for A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
- Download full text (pdf) of A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 637-647, 2018
- DOI for Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
- Download full text (pdf) of Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
Model-Informed Drug Development and Review for Generic Products: Summary Of FDA Public Workshop
Part of Clinical Pharmacology and Therapeutics, p. 27-30, 2018
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Part of CPT, p. 87-109, 2017
- DOI for Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
- Download full text (pdf) of Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Part of CPT, p. 418-429, 2017
Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 611-616, 2017
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 581-597, 2017
- DOI for Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
- Download full text (pdf) of Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
The effect of using a robust optimality criterion in model based adaptive optimization.
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 317-324, 2017
- DOI for The effect of using a robust optimality criterion in model based adaptive optimization.
- Download full text (pdf) of The effect of using a robust optimality criterion in model based adaptive optimization.
Part of AAPS Journal, p. 505-518, 2016
Accelerating Monte Carlo power studies through parametric power estimation
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 223-234, 2016
- DOI for Accelerating Monte Carlo power studies through parametric power estimation
- Download full text (pdf) of Accelerating Monte Carlo power studies through parametric power estimation
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 211-224, 2015
Part of British Journal of Clinical Pharmacology, p. 6-17, 2015
Part of Pharmaceutical research, p. 2152-2165, 2014
- DOI for Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
- Download full text (pdf) of Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 639-654, 2014
- DOI for Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
- Download full text (pdf) of Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
Part of CPT, 2013
PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool
Part of Computer Methods and Programs in Biomedicine, p. 789-805, 2012
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Part of AAPS Journal, p. 143-151, 2011
Optimal Design in Population Kinetic Experiments by Set-Valued Methods
Part of AAPS Journal, p. 495-507, 2011
Adaptive-Optimal Design in PET Occupancy Studies
Part of Clinical Pharmacology and Therapeutics, p. 563-571, 2010
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method
Part of Pharmaceutical research, p. 2187-2197, 2007
Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
Part of AAPS Journal, 2005
Robust population pharmacokinetic experiment design.
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 33-64, 2005
Recent publications
Part of CPT, p. 270-280, 2024
- DOI for Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
- Download full text (pdf) of Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
Part of CPT, p. 1748-1761, 2024
- DOI for Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
- Download full text (pdf) of Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
A fully automatic tool for development of population pharmacokinetic models
Part of CPT, p. 1784-1797, 2024
- DOI for A fully automatic tool for development of population pharmacokinetic models
- Download full text (pdf) of A fully automatic tool for development of population pharmacokinetic models
Methods for non-proportional hazards in clinical trials: A systematic review
Part of Statistical Methods in Medical Research, p. 1069-1092, 2024
- DOI for Methods for non-proportional hazards in clinical trials: A systematic review
- Download full text (pdf) of Methods for non-proportional hazards in clinical trials: A systematic review
Part of Clinical Pharmacology and Therapeutics, p. 1593-1605, 2024
- DOI for Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
- Download full text (pdf) of Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
All publications
Articles in journal
Part of CPT, p. 270-280, 2024
- DOI for Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
- Download full text (pdf) of Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
Part of CPT, p. 1748-1761, 2024
- DOI for Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
- Download full text (pdf) of Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
A fully automatic tool for development of population pharmacokinetic models
Part of CPT, p. 1784-1797, 2024
- DOI for A fully automatic tool for development of population pharmacokinetic models
- Download full text (pdf) of A fully automatic tool for development of population pharmacokinetic models
Part of Clinical Pharmacology and Therapeutics, p. 1593-1605, 2024
- DOI for Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
- Download full text (pdf) of Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
Part of CPT, p. 1734-1747, 2024
- DOI for Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points
- Download full text (pdf) of Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points
Part of CPT, p. 1327-1340, 2024
- DOI for Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias
- Download full text (pdf) of Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias
Part of Computational Statistics & Data Analysis, 2024
- DOI for Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease
- Download full text (pdf) of Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease
The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA
Part of AAPS Journal, 2024
Generation and application of avatars in pharmacometric modelling
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 411-423, 2023
- DOI for Generation and application of avatars in pharmacometric modelling
- Download full text (pdf) of Generation and application of avatars in pharmacometric modelling
How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials?
Part of Biometrics, p. 3998-4011, 2023
Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
Part of Orphanet Journal of Rare Diseases, 2023
- DOI for Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
- Download full text (pdf) of Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
Part of AAPS Journal, 2021
- DOI for Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
- Download full text (pdf) of Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Pharmacometrics meets statistics-A synergy for modern drug development
Part of CPT, p. 1134-1149, 2021
- DOI for Pharmacometrics meets statistics-A synergy for modern drug development
- Download full text (pdf) of Pharmacometrics meets statistics-A synergy for modern drug development
Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
Part of CPT, p. 1452-1465, 2021
- DOI for Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
- Download full text (pdf) of Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization
Part of Clinical Pharmacology and Therapeutics, p. 1190-1195, 2021
- DOI for Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
- Download full text (pdf) of Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence.
Part of Clinical Pharmacology in Drug Development, p. 220-228, 2021
Part of AAPS Journal, 2020
- DOI for Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
- Download full text (pdf) of Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
Part of AAPS Journal, 2020
- DOI for Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models
- Download full text (pdf) of Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models
Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis
Part of Antimicrobial Agents and Chemotherapy, 2020
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models
Part of AAPS Journal, 2019
Part of AAPS Journal, 2018
- DOI for Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group
- Download full text (pdf) of Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group
Part of AAPS Journal, 2018
- DOI for Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
- Download full text (pdf) of Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations
Part of AAPS Journal, 2018
Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
Part of AAPS Journal, 2018
- DOI for Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
- Download full text (pdf) of Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Part of AAPS Journal, 2018
- DOI for A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
- Download full text (pdf) of A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
The Standard Output: A Tool-Agnostic Modeling Storage Format
Part of CPT, p. 543-546, 2018
- DOI for The Standard Output: A Tool-Agnostic Modeling Storage Format
- Download full text (pdf) of The Standard Output: A Tool-Agnostic Modeling Storage Format
Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 637-647, 2018
- DOI for Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
- Download full text (pdf) of Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
Model-Informed Drug Development and Review for Generic Products: Summary Of FDA Public Workshop
Part of Clinical Pharmacology and Therapeutics, p. 27-30, 2018
Model Description Language (MDL): A Standard for Modeling and Simulation
Part of CPT, p. 647-650, 2017
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Part of CPT, p. 87-109, 2017
- DOI for Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
- Download full text (pdf) of Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Part of CPT, p. 418-429, 2017
Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 611-616, 2017
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 581-597, 2017
- DOI for Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
- Download full text (pdf) of Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Part of Pharmaceutical research, p. 1125-1133, 2017
The effect of using a robust optimality criterion in model based adaptive optimization.
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 317-324, 2017
- DOI for The effect of using a robust optimality criterion in model based adaptive optimization.
- Download full text (pdf) of The effect of using a robust optimality criterion in model based adaptive optimization.
Part of AAPS Journal, p. 505-518, 2016
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 609-619, 2016
- DOI for The effect of Fisher information matrix approximation methods in population optimal design calculations
- Download full text (pdf) of The effect of Fisher information matrix approximation methods in population optimal design calculations
PopED lite: an optimal design software for preclinical pharmacokinetic and pharmacodynamic studies
Part of Computer Methods and Programs in Biomedicine, p. 126-143, 2016
Accelerating Monte Carlo power studies through parametric power estimation
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 223-234, 2016
- DOI for Accelerating Monte Carlo power studies through parametric power estimation
- Download full text (pdf) of Accelerating Monte Carlo power studies through parametric power estimation
A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R
Part of Computer Methods and Programs in Biomedicine, p. 83-93, 2016
- DOI for A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R
- Download full text (pdf) of A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R
Part of CPT, p. 316-319, 2015
- DOI for Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
- Download full text (pdf) of Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
Part of British Journal of Clinical Pharmacology, p. 116-127, 2015
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 211-224, 2015
Part of British Journal of Clinical Pharmacology, p. 6-17, 2015
Part of Journal of Nutrition, p. 1674-1680, 2014
Part of Pharmaceutical research, p. 2152-2165, 2014
- DOI for Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
- Download full text (pdf) of Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 639-654, 2014
- DOI for Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
- Download full text (pdf) of Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 223-238, 2014
Optimizing disease progression study designs for drug effect discrimination
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 587-596, 2013
Part of CPT, 2013
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
Part of CPT, 2013
Simultaneous optimal experimental design for in vitro binding parameter estimation
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 573-585, 2013
Part of NeuroImage, p. 160-169, 2013
Chain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats
Part of Journal of Nutrition, p. 1573-1578, 2013
PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool
Part of Computer Methods and Programs in Biomedicine, p. 789-805, 2012
Serial correlation in optimal design for nonlinear mixed effects models
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 239-249, 2012
Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index
Part of Journal of clinical pharmacology, p. 29-38, 2012
Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children
Part of Journal of clinical pharmacology, p. 1516-1526, 2012
Part of Journal of clinical pharmacology, p. 347-360, 2012
Part of Clinical Pharmacology and Therapeutics, p. 863-871, 2012
Part of NeuroImage, p. 849-856, 2012
Part of AAPS Journal, p. 445-463, 2011
A Fast Method for Testing Covariates in Population PK/PD Models
Part of AAPS Journal, p. 464-472, 2011
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Part of AAPS Journal, p. 143-151, 2011
Optimal Design in Population Kinetic Experiments by Set-Valued Methods
Part of AAPS Journal, p. 495-507, 2011
Part of Drug Metabolism And Disposition, p. 858-863, 2011
Adaptive-Optimal Design in PET Occupancy Studies
Part of Clinical Pharmacology and Therapeutics, p. 563-571, 2010
Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children
Part of British Journal of Clinical Pharmacology, p. 557-566, 2010
Part of Pharmaceutical research, p. 866-877, 2010
Part of AAPS Journal, p. 148-154, 2009
Simultaneous optimal experimental design on dose and sample times
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 125-145, 2009
Trial treatment length optimization with an emphasis on disease progression studies
Part of Journal of clinical pharmacology, p. 323-335, 2009
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 281-295, 2009
- DOI for Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
- Download full text (pdf) of Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
Part of Clinical Pharmacology and Therapeutics, p. 111-118, 2008
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 117-137, 2008
Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier
Part of Journal of Pharmaceutical Sciences, p. 5386-5400, 2008
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method
Part of Pharmaceutical research, p. 2187-2197, 2007
Automated identification of axonal growth cones in time-lapse image sequences.
Part of Journal of Neuroscience Methods, p. 232-8, 2006
Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
Part of AAPS Journal, 2005
Robust population pharmacokinetic experiment design.
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 33-64, 2005
POPED, a software for optimal experiment design in population kinetics.
Part of Computer Methods and Programs in Biomedicine, p. 29-46, 2004
An evaluation of population D-optimal designs via pharmacokinetic simulations.
Part of Annals of Biomedical Engineering, p. 98-111, 2003
Part of Circulation, p. 851-6, 2003
Classical examination of the Stark effect in hydrogen
Part of Physical Review A. Atomic, Molecular, and Optical Physics, p. 4609-4612, 1997
Articles, review/survey
Methods for non-proportional hazards in clinical trials: A systematic review
Part of Statistical Methods in Medical Research, p. 1069-1092, 2024
- DOI for Methods for non-proportional hazards in clinical trials: A systematic review
- Download full text (pdf) of Methods for non-proportional hazards in clinical trials: A systematic review
Part of CPT, p. 624-630, 2023
- DOI for Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop
- Download full text (pdf) of Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop
Metaheuristics for pharmacometrics
Part of CPT, p. 1297-1309, 2021
- DOI for Metaheuristics for pharmacometrics
- Download full text (pdf) of Metaheuristics for pharmacometrics
Population pharmacometrics in support of analgesics studies
Part of Acta Anaesthesiologica Scandinavica, p. 143-156, 2014